Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties
Menées in vitro et à l'aide de modèles murins, ces deux études mettent en évidence l'activité antitumorale d'un composé appelé SSR128129E qui, par des mécanismes allostériques, inhibe la signalisation du récepteur FGFR
Receptor tyrosine kinases (RTK) are targets for anticancer drug development. To date, only RTK inhibitors that block orthosteric binding of ligands and substrates have been developed. Here, we report the pharmacologic characterization of the chemical SSR128129E (SSR), which inhibits fibroblast growth factor receptor (FGFR) signaling by binding to the extracellular FGFR domain without affecting orthosteric FGF binding. SSR exhibits allosteric properties, including probe dependence, signaling bias, and ceiling effects. Inhibition by SSR is highly conserved throughout the animal kingdom. Oral delivery of SSR inhibits arthritis and tumors that are relatively refractory to anti-vascular endothelial growth factor receptor-2 antibodies. Thus, orally-active extracellularly acting small-molecule modulators of RTKs with allosteric properties can be developed and may offer opportunities to improve anticancer treatment.
º We identified an extracellular allosteric RTK inhibitor (SSR)
º SSR is a multi-FGFR inhibitor with evolutionary conserved activity
º SSR inhibits tumor growth and metastasis in various models
º SSR amplifies the activity of anti-VEGFR2 in refractory tumor models
Cancer cell , article en libre accès, 2012